Cargando…
Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
Background: Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine practice. To help understand these patterns, a retrospective study was conducted and is reported here. Met...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Columbia Data Analytics, LLC
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471399/ https://www.ncbi.nlm.nih.gov/pubmed/37663582 http://dx.doi.org/10.36469/9894 |